Mandate Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Vinge is awarded “The Top Firm in Sweden” in WTR 1000’s latest ranking

Vinge receives the highest ranking in the World Trademark Review list of the year’s rankings. The firm obtains the Guide’s foremost ranking, which also highlights specific experts.
February 18, 2021

Insurance services in Sweden – a summary 2021

Vinge’s insurance team has written a brief summary of some of the main features of the Swedish regulations affecting foreign insurers with existing or contemplated business activities in Sweden.
February 09, 2021

Summary of employment related news in Sweden as of January 2021

Short-time work, a new pandemic law and pending changes to the Employment Protection Act. Here is the latest employment related news in Sweden.
January 19, 2021